Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn’s disease and ulcerative colitis – experiences from a single center

Farkas, Klaudia, Rutka, Mariann, Ferenci, Tamás, Nagy, Ferenc, Bálint, Anita, Bor, Renáta, Milassin, Ágnes, Fábián, Anna, Szántó, Kata, Végh, Zsuzsanna, Kürti, Zsuzsanna, Lakatos, Péter László, Szepes, Zoltán, Molnár, Tamás: Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn’s disease and ulcerative colitis – experiences from a single center.
EXPERT OPINION ON BIOLOGICAL THERAPY, 17 (11). pp. 1325-1332. ISSN 1471-2598 (2017)

[img]
Preview
Text
3269325_Farkas_Exp.Opin.pdf - Accepted Version

Download (2MB) | Preview
Item Type: Article
Journal or Publication Title: EXPERT OPINION ON BIOLOGICAL THERAPY
Date: 2017
Volume: 17
Number: 11
Page Range: pp. 1325-1332
ISSN: 1471-2598
Faculty: Faculty of Medicine
Institution: Szegedi Tudományegyetem
MTMT id: 3269325
DOI id: https://doi.org/10.1080/14712598.2017.1363885
Date Deposited: 2017. Oct. 26. 10:56
Last Modified: 2020. Feb. 13. 10:20
URI: http://publicatio.bibl.u-szeged.hu/id/eprint/12187
Web of Science® Times Cited: 12 View citing articles in Web of Science®

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year